Manager TitleAgeSince
President 63 26/05/2010
Director TitleAgeSince
Director/Board Member 63 25/03/2010
Director/Board Member 85 31/05/2011
Director/Board Member 79 08/05/2013
Change 5-day change 1-year change 3-year change Capi.($)
+0.03%+0.40% - - 0
-4.83%+3.51%+55.00%+62.02% 66.7B
+3.60%+7.73%+13.34%+83.41% 56.88B
+0.59%+2.87%+24.87%+96.58% 56.53B
+5.09%+9.89%+27.19%+103.27% 46.49B
+2.62%+1.68%+29.16%+36.08% 44.8B
+8.24%+0.51%+215.16%+807.84% 41.59B
-1.86%+10.13%+28.14%+53.61% 35.35B
+3.03%-1.73%+93.76%+65.56% 33.29B
+5.19%+1.62%-39.69%+381.71% 25.1B
Average +2.16%+2.65%+49.66%+187.78% 45.19B
Weighted average by Cap. +1.90%+3.07%+50.33%+167.22%
Logo TESARO Inc
TESARO, Inc. is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform. Rolapitant is a potent and long-acting neurokinin-1 receptor antagonist for the prevention of chemotherapy induced nausea and vomiting. Niraparib is an orally active and potent poly (adenosine diphosphate (ADP)-ribose) polymerase inhibitor. It has various ongoing clinical trials evaluating niraparib for the treatment of ovarian or breast cancers. It has initiated a Phase I, dose escalation study for its first immuno-oncology antibody, TSR-042, which targets Programmed cell death protein 1. It has commenced pre-clinical research for its antibody candidate targeting Lymphocyte-activation gene-3 andTSR-033. It has commenced a Phase I clinical trial of TSR-042.
Employees
-